CVRM News

Revelation Biosciences, Inc. has announced the formation of an Acute Kidney Injury (AKI) Advisory Board to guide its upcoming Phase 2/3 clinical trial for the treatment of AKI using its proprietary formulation, Gemini. The board consists of renowned nephrologists and critical care physicians who will assist in clinical strategy and study design to address the unmet medical needs in AKI. The initiative aims to improve patient care by advancing Gemini, which modulates the innate immune response rather than merely suppressing inflammation. The advisory board includes experts such as Dr. Laurence Busse, Dr. Sean Bagshaw, Dr. Stuart Goldstein, Dr. Javier Neyra, and Dr. Alexander Zarbock, each bringing extensive experience in critical care nephrology and research. Gemini is also being explored for other conditions, including chronic kidney disease and severe burn-related infections, with prior positive results in preclinical models and phase 1 studies.

Read full article: https://www.biospace.com/press-releases/revelation-biosciences-announces-formation-of-acute-kidney-injury-advisory-board

Subscribe to our real-time email alerts: https://www.stellarint.ai/Services/

The 2026 update of the American Association of Clinical Endocrinology's (AACE) consensus statement algorithm for type 2 diabetes introduces significant changes, including a new chart for diabetes classification and the recognition of metabolic dysfunction-associated steatotic liver disease (MASLD) as a comorbidity. This update, the first since 2023, reflects advancements in diabetes medications and aims to improve diagnostic accuracy by considering various forms of diabetes. Key principles emphasize lifestyle interventions, individualized treatment plans, and the importance of managing comorbidities. The algorithm also incorporates new therapies and ghlights cost-effectiveness in treatment decisions. Overall, it aims to streamline the management of type 2 diabetes amidst rising global prevalence.

Read full article: https://www.healio.com/news/endocrinology/20260406/diabetes-classifications-new-medications-focus-of-2026-aace-type-2-diabetes-algorithm

Subscribe to our real-time email alerts: https://www.stellarint.ai/Services/

🏢 Novo Nordisk 🫀 obesity
Novo Nordisk is experiencing a significant leadership change as a prominent figure in the GLP-1 obesity treatment sector, Lotte Bjerre Knudsen, retires. This transition comes at a time when the company is facing increased competition in the obesity market, particularly with Boehringer Ingelheim gaining a key player. The article ghlights the implications of this departure for Novo Nordisk's position in the industry and the ongoing developments in obesity treatment.

Read full article: https://endpoints.news/novo-glp-1-luminary-retires-as-it-loses-an-obesity-leader-to-boehringer-ingelheim/

Subscribe to our real-time email alerts: https://www.stellarint.ai/Services/

Diamyd Medical has announced the discontinuation of its Phase 3 DIAGNODE-3 trial evaluating retogatein (rhGAD65) for Stage 3 type 1 diabetes due to interim results indicating futility. The analysis, based on 174 participants, showed no significant effect on C-peptide levels, a marker for insulin secretion, and did not meet the criteria for continuation. No new safety concerns were identified, and the company will proceed with an orderly wind-down of the trial while prioritizing patient safety. Additionally, Diamyd Medical's Board of Directors has initiated a strategic review to explore alternatives for maximizing shareholder value, which may include evaluating external assets and partnerships. The company will also assess its biomanufacturing capabilities in Umeå, Sweden, where it is developing a facility for retogatein production. Retogatein has received Orphan Drug and Fast Track Designations from the U.S. FDA for treating type 1 diabetes.

LifeMD, Inc. has announced the addition of Foundayo™ (orforglipron), a new oral GLP-1 therapy for weight management developed by Eli Lilly and Company, to its weight management program. Approved by the FDA on April 1, 2026, Foundayo is designed for adults with obesity or overweight conditions and is available through LifeMD's integration with LillyDirect®, allowing for direct prescription fulfillment. The self-pay price starts at $149 per month, with potential lower costs for patients with commercial insurance. LifeMD aims to enhance access to affordable weight management care, providing comprehensive support including virtual consultations and educational resources. This addition reinforces LifeMD's position in offering FDA-approved weight management medications.

Read full article: https://www.biospace.com/press-releases/lifemd-now-offering-eli-lilly-and-companys-foundayo-orforglipron-a-new-glp-1-pill-for-weight-management

Subscribe to our real-time email alerts: https://www.stellarint.ai/Services/

🏢 Viking Therapeutics, Inc.
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for metabolic and endocrine disorders, announced its participation in upcoming investor conferences. The company will engage in one-on-one meetings at the Raymond James Biotech/BioPharma Conference on April 14, 2026, in New York, and at the Piper Sandler Spring Biopharma Symposium on April 16, 2026, in Boston. Viking's clinical programs include VK2735, a dual agonist for metabolic disorders currently in Phase 3 trials, and VK2809, a thyroid hormone receptor beta agonist that has shown positive results in Phase 2 studies for non-alcoholic steatohepatitis and fatty liver disease. Additionally, Viking is developing VK0214 for X-linked adrenoleukodystrophy, which has demonstrated safety and efficacy in early trials.

The European Medicines Agency (EMA) has approved an update to the product information for Wegovy® injection, allowing it to be delivered at controlled temperatures of up to 30°C for up to 48 hours. This makes Wegovy® the first GLP-1 medication for weight management in Europe with such delivery flexibility, reducing the need for cold chain transport and potentially lowering delivery costs for pharmacies and online partners. The update aims to facilitate home delivery options for patients, particularly those with obesity, while maintaining the existing patient leaflets. Wegovy® is indicated for weight management in adults and pediatric patients aged 12 and older, and is also approved for reducing the risk of major cardiovascular events in adults with known heart disease. Novo Nordisk, the manufacturer, emphasizes the importance of evolving distribution practices in the healthcare industry.

Unicycive Therapeutics, Inc., a clinical-stage biotechnology company focused on kidney disease therapies, announced that CEO Shalabh Gupta, M.D., will present at the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026. The company is developing oxylanthanum carbonate, a phosphate binding agent under FDA review for treating hyperphosphatemia in chronic kidney disease patients on dialysis. Additionally, Unicycive's investigational treatment UNI-494, which has received orphan drug designation for preventing Delayed Graft Function in kidney transplant patients, has completed a Phase 1 safety study in healthy volunteers. More information is available on their website.

Read full article: https://ir.unicycive.com/news/detail/121/unicycive-therapeutics-to-present-at-the-25th-annual

Subscribe to our real-time email alerts: https://www.stellarint.ai/Services/

A study by 23andMe has analyzed the genomes of nearly 28,000 users of GLP-1 agonist-based weight-loss drugs, such as Wegovy and Zepbound, to understand the variability in patient responses. The research identified genetic variations in the GLP1R and GIPR genes that influence weight loss outcomes and susceptibility to side effects. The findings suggest that genetic testing could help tailor weight-loss treatments to individual patients, potentially improving efficacy and safety. However, experts note that while genetics play a role, non-genetic factors like sex, drug type, and dosage have a more significant impact on treatment variability. The study aims to advance personalized approaches to weight management, addressing the current trial-and-error method in obesity treatment.

Read full article: https://pharmaphorum.com/news/23andme-study-explains-variable-results-obesity-drugs

Subscribe to our real-time email alerts: https://www.stellarint.ai/Services/

🏢 Novartis 🫀 heart disease, cancer
Novartis has announced an expansion of its community health programs aimed at addressing gaps in heart disease and cancer care, targeting over 30 countries by 2030. The initiative includes three main approaches: Inclusive Health Accelerators (IHAs) to improve access to cancer care in five U.S. cities, Community Health Initiatives (CHIs) to enhance diagnosis and treatment in low- and middle-income countries, and CARDIO4Cities, which utilizes real-time data to improve heart health in urban areas. The expansion builds on successful pilot programs that have shown significant improvements in health outcomes, such as increased control rates for gh blood pressure. The programs will involve collaboration with local organizations to enhance prevention, early detection, and follow-up care for underserved populations.

Vanda Pharmaceuticals Inc. has announced the initiation of Thetis, a clinical trial to evaluate NEREUS™ (tradipitant) for preventing vomiting in patients undergoing treatment with GLP-1 receptor agonists, which are commonly used for type 2 diabetes and obesity. The trial aims to address gastrointestinal side effects, particularly nausea and vomiting, which can lead to treatment discontinuation. NEREUS™ has previously shown effectiveness in reducing vomiting in earlier studies. The Thetis study will be a multicenter, randomized, double-blind, placebo-controlled trial, with the primary endpoint being the proportion of patients free from vomiting episodes. Vanda expects to report topline results by Q4 2026, and additional data may be required for a New Drug Application (NDA) approval following the study's completion.

NewAmsterdam Pharma Company N.V., a late-stage clinical biopharmaceutical company focused on developing oral, non-statin medicines for patients at risk of cardiovascular disease with elevated low-density lipoprotein cholesterol, announced that its CFO Ian Somaiya and EVP Matthew Philippe will participate in a virtual fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026. The event will be accessible via a live webcast on the company's investor relations website, with an archived replay available afterward. NewAmsterdam is conducting multiple phase 3 trials for obicetrapib, a CETP inhibitor aimed at providing effective LDL-C lowering therapies for patients who do not respond well to existing treatments.

Read full article: https://ir.newamsterdampharma.com/news-releases/news-release-details/newamsterdam-pharma-present-25th-annual-needham-virtual

Subscribe to our real-time email alerts: https://www.stellarint.ai/Services/

🏢 Ambrosia Biosciences 🫀 obesity
Ambrosia Biosciences has raised $100 million in a Series B funding round to develop next-generation small molecule GLP-1 agonists for obesity treatment. The funding will support a Phase 1 study of its lead asset and advance its small-molecule pipeline, which also targets other cardiometabolic pathways. The round was co-led by new investors including Blue Owl Healthcare Opportunities, Redmile, and Deep Track Capital, with additional support from BVF Partners, Boulder Ventures, Samsara BioCapital, and Janus Henderson Investors. Unlike the currently dominant peptide-based GLP-1 treatments, Ambrosia aims to create small-molecule pills that offer better oral bioavailability and easier manufacturing. The company seeks to differentiate its products in a market that includes established drugs like Novo Nordisk's semaglutide and Eli Lilly's tirzepatide, as well as the upcoming orforglipron, a small molecule under FDA review.

Read full article: https://www.biospace.com/business/ambrosia-eyes-next-generation-small-molecule-glp-1s-with-100m-series-b

Subscribe to our real-time email alerts: https://www.stellarint.ai/Services/

Skye Bioscience, a clinical-stage biotechnology company, will present at the GLP-1-Based Therapeutics Summit in Boston from April 14-16, 2026. The presentation, titled 'Maximizing Efficacy, Minimizing Risk by Leveraging Peripheral CB1 Antagonism in Combination with GLP-1 Agonists to Advance the Obesity Treatment Paradigm,' will be delivered by Punit Dhillon, the company's President & CEO, on April 16. Skye is developing nimacimab, a monoclonal antibody designed to inhibit the CB1 receptor without affecting the central nervous system, potentially reducing neuropsychiatric side effects. Nimacimab is being studied as an add-on therapy for patients with obesity who have plateaued on GLP-1 treatments, aiming for improved weight loss and body composition. The company is currently conducting a Phase 2a clinical trial to evaluate nimacimab's efficacy in combination with GLP-1R agonist semaglutide.

Read full article: https://www.biospace.com/press-releases/skye-bioscience-presenting-at-glp-1-based-therapeutics-summit

Subscribe to our real-time email alerts: https://www.stellarint.ai/Services/

A study published in the Clinical Journal of the American Society of Nephrology indicates that semaglutide (Ozempic, Novo Nordisk) significantly improves kidney outcomes and survival rates among patients with type 2 diabetes and chronic kidney disease (CKD). The FLOW trial, which involved 3,533 participants, found that those treated with semaglutide experienced lower risks for adverse kidney outcomes and all-cause mortality compared to a placebo group. Specifically, semaglutide reduced the risk of a composite kidney outcome by 24% and all-cause death by 20%. The benefits were consistent across various stages of CKD, particularly for patients with severe CKD and gh albuminuria levels. Researchers suggest further studies are needed to explore the effects of semaglutide in diverse patient populations and in combination with other treatments for CKD.

Read full article: https://www.healio.com/news/nephrology/20260407/semaglutide-demonstrates-kidney-survival-improvements-across-ckd-spectrum

Subscribe to our real-time email alerts: https://www.stellarint.ai/Services/

Novo Nordisk has announced the nationwide availability of Wegovy® HD (semaglutide) injection 7.2 mg, which is now accessible through over 70,000 US pharmacies and select telehealth providers. This new formulation is designed for adults with obesity, offering an average weight loss of approximately 21% over 72 weeks, as demonstrated in the STEP UP trial. Wegovy® HD is the ghest dose of Wegovy® to date and is intended for patients who may not have achieved their weight loss goals with lower doses. The drug is also noted for its cardiovascular benefits, reducing the risk of major events in patients with known heart disease. Common side effects include nausea, vomiting, and dysesthesia, with a gher incidence of skin sensation alterations reported in the Wegovy® HD group. Pricing for self-pay patients starts at $399/month, while commercially insured patients may pay as little as $25/month. The FDA approval was based on a comprehensive clinical trial involving 1,407 adults with obesity.

Read full article: https://finance.yahoo.com/sectors/healthcare/articles/novo-nordisks-wegovy-hd-available-120000475.html

Subscribe to our real-time email alerts: https://www.stellarint.ai/Services/

Eli Lilly's fair value per share has been slightly adjusted from $1,211.21 to $1,209.21, reflecting ongoing analysis of its obesity and diabetes treatments, particularly the recent FDA approval of Foundayo (orforglipron). Analysts from various firms have raised price targets for Eli Lilly, citing confidence in its obesity and diabetes franchise, while others, like HSBC, have reduced their ratings due to gh market expectations and potential price competition. Eli Lilly plans to invest $3 billion in China over the next decade and has built a $1.5 billion pre-launch inventory of orforglipron. The company is also investing over $3.5 billion in a new manufacturing facility in Pennsylvania for injectable medicines and next-generation weight loss therapies. The article emphasizes the importance of tracking analyst forecasts and market dynamics as they relate to Eli Lilly's growth prospects in the obesity and diabetes sectors.

Read full article: https://uk.finance.yahoo.com/news/eli-lilly-lly-obesity-diabetes-021127573.html

Subscribe to our real-time email alerts: https://www.stellarint.ai/Services/

Novo Nordisk CEO Mike Doustdar stated that the demand for obesity treatments, particularly weight-loss drugs like Wegovy and Ozempic, is just beginning to be realized. He emphasized the importance of expanding access to these treatments as a priority for pharmaceutical companies. This statement reflects the growing market potential for obesity medications.

Read full article: https://seekingalpha.com/news/4572534-novo-nordisk-ceo-says-weight-loss-drug-boom-has-barely-begun

Subscribe to our real-time email alerts: https://www.stellarint.ai/Services/

AstraZeneca has provided an update on its Phase I clinical trial for AZD6234, an experimental injectable drug aimed at individuals with overweight or obesity. The trial, which has now reached 'Completed' status, evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of the drug through a randomized, single-blind, placebo-controlled study design. Participants received repeated doses of either AZD6234 or a placebo, with the study including cohorts of Japanese participants to assess potential differences in safety or dosing. Although formal results have not yet been posted, the completion of this early study is seen as a positive indicator for AstraZeneca's ambitions in the obesity treatment market, which is currently dominated by competitors Novo Nordisk and Eli Lilly. The trial began on November 10, 2023, and was last updated on April 2, 2026, reflecting new safety or dosing information.

Read full article: https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/1145520/astrazeneca-completes-early-obesity-trial-for-azd6234-nudging-long-term-growth-hopes/

Subscribe to our real-time email alerts: https://www.stellarint.ai/Services/

The Emirates Drug Establishment (EDE) has approved Foundayo™ (orforglipron), an innovative oral treatment for chronic weight management, making the UAE the second country globally to register this medication developed by Eli Lilly. This approval is part of EDE's efforts to enhance access to pharmaceutical innovations and improve patient experiences by providing oral alternatives to injections. Orforglipron is a once-daily oral glucagon-like peptide-1 (GLP-1) receptor agonist that aids in appetite regulation and weight reduction, supporting long-term management of obesity. Clinical trials have shown significant weight loss results, with participants on the ghest dose losing an average of 12.4%. The treatment is expected to be available to eligible patients starting May 2026, reflecting the UAE's commitment to addressing obesity and its associated health risks.

Read full article: https://www.tradingview.com/news/reuters.com,2026-04-04:newsml_Zaw6rn1SK:0-zawya-emirates-drug-establishment-approves-oral-obesity-treatment-marking-shift-away-from-injections/

Subscribe to our real-time email alerts: https://www.stellarint.ai/Services/

Novo Nordisk has reduced the prices of its obesity drugs, Wegovy and Ozempic, by up to 48% in India due to increased competition from generic semaglutide, leading to a 43% decline in its share price over the past year. The company's 2026 guidance indicates a potential adjusted sales growth decline of 5% to 13%. Novo Nordisk is awaiting an FDA decision on CagriSema, a combination of cagrilintide and semaglutide, expected by early 2027, which is seen as crucial for the company's recovery. Eli Lilly currently dominates the U.S. obesity drug market with over 60% market share, further pressuring Novo Nordisk's margins. Recent sentiment on social media regarding Novo Nordisk has fluctuated, reflecting concerns over its pricing power and market position amidst ongoing competition and regulatory challenges.

Read full article: https://finance.yahoo.com/sectors/healthcare/articles/novo-nordisk-shares-down-43-161059523.html

Subscribe to our real-time email alerts: https://www.stellarint.ai/Services/

Viking Therapeutics has completed patient enrollment in its Phase 3 VANQUISH-2 trial for VK2735, a dual GLP-1/GIP agonist aimed at treating obesity in adults with type 2 diabetes. The trial will evaluate the drug over 78 weeks, focusing on body-weight change as the primary endpoint. This milestone follows positive Phase 2 results showing significant weight loss and a favorable tolerability profile. While the completion of enrollment reduces some execution risks, the company still faces challenges, including heavy R&D spending and potential delays in revenue generation. Analysts have varying projections for VK2735's future revenue and earnings, with some viewing the completed trials as pivotal for Viking's valuation and commercial strategy. The article emphasizes the importance of upcoming data readouts for the company's financial outlook and investment narrative.

Read full article: https://finance.yahoo.com/sectors/healthcare/articles/did-vk2735-vanquish-2-enrollment-131123183.html

Subscribe to our real-time email alerts: https://www.stellarint.ai/Services/

💊 retatrutide 🫀 type 2 diabetes
Retatrutide has shown significant reductions in A1C levels and weight loss in a Phase 3 trial for type 2 diabetes. The trial results indicate that the drug may be an effective treatment option for managing blood sugar levels and aiding in weight management for patients with this condition.

Read full article: https://www.pharmacytimes.com/view/retatrutide-delivers-significant-a1c-reduction-weight-loss-in-phase-3-type-2-diabetes-trial

Subscribe to our real-time email alerts: https://www.stellarint.ai/Services/

Bayer's subsidiary, AskBio Inc., has completed patient enrollment in the mid-stage GenePHIT study for AB-1002, a gene therapy for heart failure with reduced ejection fraction (HFrEF), involving 173 participants. The phase II trial aims to evaluate the safety and efficacy of a single-dose gene therapy delivered to the heart. Initial results are expected in the first half of 2027. Bayer is also expanding its cardiovascular portfolio, with recent approvals for Kerendia (finerenone) and Beyonttra (acoramidis), and is advancing other therapies like asundexian for stroke prevention. The company reported strong growth and multiple pipeline milestones, with a focus on innovation in precision cardiology and gene therapy. Bayer's diverse portfolio includes several key assets and strategic partnerships, positioning it for sustained growth in the coming years.

Read full article: https://finance.yahoo.com/sectors/healthcare/articles/bayer-advances-ab-1002-study-182900823.html

Subscribe to our real-time email alerts: https://www.stellarint.ai/Services/

🏢 Alnylam Pharmaceuticals
Barclays analyst Eliana Merle has maintained a Buy rating on Alnylam Pharmaceuticals, setting a price target of $527.00. Merle, a 3-star analyst, has an average return of 3.1% and a 39.73% success rate, focusing on the Healthcare sector. Alnylam also received a Buy rating from Piper Sandler's Edward Tenthoff, while Morgan Stanley reiterated a Hold rating. For the quarter ending December 31, Alnylam reported a revenue of $1.1 billion and a net profit of $186.42 million, a significant improvement from the previous year's revenue of $593.17 million and a net loss of $83.76 million. However, insider sentiment has turned negative, with an increase in insiders selling shares, including a notable sale by EVP & CFO Jeffrey V. Poulton. Recent data presentations on Alnylam's products, including vutrisiran and zilebesiran, have been ghlighted as part of their ongoing research efforts.

Read full article: https://www.theglobeandmail.com/investing/markets/stocks/ALNY-Q/pressreleases/1109329/alnylam-pharma-alny-gets-a-buy-from-barclays/

Subscribe to our real-time email alerts: https://www.stellarint.ai/Services/

🏢 Aspect Biosystems Ltd. 🫀 diabetes
Aspect Biosystems Ltd., based in Vancouver, has received $79 million in federal funding to enhance its capacity for 3-D printing live tissue implants aimed at replacing organ functions. This funding is part of a larger $280 million multi-year project that will support the development of bioengineered cellular medicines for serious metabolic and endocrine diseases. The B.C. government is also contributing $23.75 million to the project. Aspect has previously partnered with Novo Nordisk, which has invested significantly in the company and holds exclusive rights to develop products targeting diabetes and obesity using Aspect's technology. Although Aspect's technology has not yet been tested in humans, it aims to create synthetic tissues that can be implanted to restore organ functions. The company has raised over $250 million in venture capital and employs around 130 people, with aspirations to become a major player in the biopharma sector in Canada.

Read full article: https://www.theglobeandmail.com/business/technology/article-aspect-biosystems-secures-79-million-in-federal-funding-to-advance-3-d/

Subscribe to our real-time email alerts: https://www.stellarint.ai/Services/

Skye Bioscience, Inc. has initiated the first patient treatment in Part C of its CBeyond Phase 2a trial, focusing on the safety and pharmacokinetics of nimacimab, a monoclonal antibody aimed at obesity and metabolic disorders. The study will evaluate two dosing cohorts (400 mg and 600 mg IV) against a placebo over 15 weeks, with a follow-up period of 12 weeks. This expansion aims to establish a safety profile for gher doses of nimacimab, which has previously shown promising results in combination with semaglutide, achieving a 22.3% mean weight loss at 52 weeks. The FDA has provided feedback on the proposed Phase 2b trial design, which will be refined based on the outcomes of Part C. Skye anticipates reporting topline data from this expansion study in Q4 2026. Nimacimab is designed to avoid central nervous system penetration, potentially reducing neuropsychiatric side effects associated with other treatments.

Read full article: https://www.globenewswire.com/news-release/2026/04/02/3267226/0/en/Skye-Bioscience-Treats-First-Patient-in-Nimacimab-Higher-Dose-Expansion-Study-Evaluating-Exposure-Response-to-Inform-Phase-2b-Dose-Selection-for-GLP-1-Combination-Development.html

Subscribe to our real-time email alerts: https://www.stellarint.ai/Services/

Novo Nordisk has received FDA approval for a gh-dose version of its anti-obesity drug Wegovy, which demonstrated improved efficacy in clinical trials, achieving an average weight loss of 18.8% compared to 15.5% for the original formulation. Despite this advancement, Novo Nordisk is unlikely to regain its leading position in the weight loss market, primarily due to competition from Eli Lilly's Zepbound, which has shown superior results and additional indications. Novo Nordisk is also advancing other candidates in its pipeline, such as Amycretin and UBT251, which could enhance its market position in the future. However, analysts suggest that the stock may not be an immediate buy, as it was not included in a list of top investment recommendations.

Read full article: https://www.theglobeandmail.com/investing/markets/markets-news/Motley%20Fool/1097480/could-this-new-approval-be-a-turning-point-for-novo-nordisk/

Subscribe to our real-time email alerts: https://www.stellarint.ai/Services/

The FDA has approved Eli Lilly's Foundayo™ (orforglipron), a GLP-1 oral medication for weight loss that can be taken without food or water restrictions. In the ATTAIN-1 clinical trial, adults using the ghest dose lost an average of 27.3 pounds, significantly more than those on placebo. Foundayo is intended for adults with obesity or overweight with related medical issues, and is to be used alongside a reduced-calorie diet and increased physical activity. It will be available through LillyDirect with a starting price of $25 per month for those with commercial insurance. The drug may cause serious side effects, including potential thyroid tumors, and is not recommended for use with other GLP-1 receptor agonists. Foundayo is also being studied for other conditions, including type 2 diabetes and hypertension. Eli Lilly plans to launch orforglipron in over 40 countries following its approval.

Read full article: https://www.prnewswire.com/news-releases/fda-approves-lillys-foundayo-orforglipron-the-only-glp-1-pill-for-weight-loss-that-can-be-taken-any-time-of-day-without-food-or-water-restrictions-302731485.html

Subscribe to our real-time email alerts: https://www.stellarint.ai/Services/

The NHS will offer the weight-loss drug Wegovy, also known as semaglutide, for free to over a million people in England at risk of heart attacks and strokes. The National Institute for Health and Care Excellence (NICE) recommends the weekly injection as an additional protective measure for overweight individuals with existing heart conditions. Clinical trials indicate that Wegovy can reduce the risk of heart attacks and strokes by 20%, even before significant weight loss occurs. Patients will self-administer the drug at home, and it is advised for those with a Body Mass Index (BMI) of 27 or gher. The rollout is expected to begin this summer, although treatment is currently limited to two years. NICE has reached a cost-effective agreement with the drug's manufacturer, Novo Nordisk. Experts emphasize the importance of lifestyle changes alongside medication and caution about potential side effects, including muscle mass reduction. The long-term risks of Wegovy are still under investigation.

Read full article: https://www.bbc.com/news/articles/cz90595pgzlo

Subscribe to our real-time email alerts: https://www.stellarint.ai/Services/

Gan & Lee Pharmaceuticals announced that its once-weekly basal insulin GZR4 Injection has met primary endpoints in two pivotal Phase 3 clinical trials, SUPER-1 and SUPER-2. In SUPER-1, which involved 588 insulin-naïve adults with type 2 diabetes mellitus (T2DM), GZR4 showed a statistically significant reduction in glycated hemoglobin A1c (HbA1c) compared to insulin glargine U100 after 26 weeks. Similarly, in SUPER-2, involving 631 patients previously treated with basal insulin, GZR4 outperformed insulin degludec in HbA1c reduction. Both trials demonstrated favorable safety profiles with no severe hypoglycemic events reported. The results are set to be presented at a scientific conference and submitted for publication. GZR4 aims to provide a more convenient treatment option for T2DM patients, reducing injection frequency and potentially improving adherence and quality of life.

Read full article: https://en.prnasia.com/releases/apac/gan-lee-pharmaceuticals-once-weekly-basal-insulin-gzr4-injection-meets-primary-endpoints-in-two-pivotal-phase-3-clinical-trials-super-1-and-super-2-527591.shtml

Subscribe to our real-time email alerts: https://www.stellarint.ai/Services/

Bayer has received European Commission approval to expand the use of its drug Kerendia (finerenone) for treating adults with heart failure (HF) with left ventricular ejection fraction (LVEF) of 40% or gher. This approval is based on the phase III FINEARTS-HF study, which showed that finerenone significantly reduced cardiovascular death and heart failure events compared to placebo. Kerendia is already approved in over 100 countries for chronic kidney disease associated with type II diabetes. The ongoing MOONRAKER program aims to evaluate finerenone across various patient populations. Bayer's sales of Kerendia reached €829 million in 2025, reflecting a 79% increase from the previous year. The company is also focusing on expanding its portfolio with new products and has seen a significant rise in its stock value over the past year. Additionally, Bayer is addressing ongoing litigation related to its Roundup product, which has impacted investor sentiment.

Read full article: https://finance.yahoo.com/sectors/healthcare/articles/bayer-wins-ec-approval-expand-174400119.html

Subscribe to our real-time email alerts: https://www.stellarint.ai/Services/

Biogen Inc. has announced its agreement to acquire Apellis Pharmaceuticals for $41 per share in cash, totaling approximately $5.6 billion. This acquisition will enhance Biogen's portfolio with two FDA-approved immunology medicines: EMPAVELI, which treats rare kidney diseases, and SYFOVRE, approved for geographic atrophy, an immune-mediated retinal disease. The combined revenue from these products was $689 million in 2025, with expected growth in the mid-to-gh teens through 2028. The acquisition aims to strengthen Biogen's commercial capabilities in nephrology and is anticipated to be accretive to Biogen's earnings per share starting in 2027. Biogen plans to finance the acquisition through cash and borrowings, with expectations to maintain financial flexibility for future investments. The transaction is expected to close in the second quarter of 2026, pending regulatory approvals and other customary conditions.

Read full article: https://www.theglobeandmail.com/investing/markets/stocks/BIIB/pressreleases/1059545/biogen-to-acquire-apellis-enhancing-the-companys-growth-portfolio-in-immunology-and-rare-disease-bolstering-growth-outlook-and-accelerating-expansion-into-nephrology/

Subscribe to our real-time email alerts: https://www.stellarint.ai/Services/

Galectin Therapeutics, Inc. reported its financial results for the year ending December 31, 2025, ghlighting progress in its belapectin development program for treating metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension. The company noted a 43.2% reduction in varices incidence in the intent-to-treat population and a 49.3% reduction in the per-protocol population treated with belapectin compared to placebo. Financially, Galectin improved its position with a $10 million line of credit and reported a net loss of $31 million, down from $47.2 million in 2024. The company plans to present new findings at the upcoming EASL Congress and is preparing for an FDA meeting in the second quarter of 2026 to discuss the next steps for belapectin. Galectin aims to address the unmet medical needs in MASH cirrhosis, where no approved therapies currently exist.

Read full article: https://www.biospace.com/press-releases/galectin-therapeutics-reports-2025-financial-results-and-provides-business-update

Subscribe to our real-time email alerts: https://www.stellarint.ai/Services/

🏢 Blackstone
Blackstone has announced the closure of its BXLS VI life sciences fund with $6.3 billion in capital commitments, marking it as the largest private fund in the sector to date. This fund is 40% larger than its predecessor, which closed in 2020 at $4.6 billion, reflecting a positive shift in investor sentiment towards life sciences and healthcare. Since its inception in 2018, the BXLS program has facilitated significant investments, including collaborations with Alnylam and Moderna, and has achieved 34 regulatory approvals for innovative medicines and devices. The fund primarily targets later-stage drug development assets with gh commercial potential, boasting an 86% regulatory approval rate for its phase 3 assets, which exceeds the industry average. Blackstone's life sciences strategy has resulted in successful product launches, including Alnylam's Amvuttra and Novartis' Leqvio.

Read full article: https://pharmaphorum.com/news/blackstone-closes-record-63bn-life-sciences-fund

Subscribe to our real-time email alerts: https://www.stellarint.ai/Services/

Novo Nordisk has reduced the prices of its diabetes and weight-loss medications, Ozempic and Wegovy, by up to 48% in India, following the expiration of the patent on their active ingredient, semaglutide. The price cuts, which affect the lowest doses of both drugs, aim to counter the emergence of cheaper generics from local pharmaceutical companies. The new prices are set at Rs 1,415 ($15.04) for the 0.25 mg weekly dose of Ozempic and Rs 1,415 for Wegovy, down from previous prices of Rs 2,200 and Rs 2,712, respectively. This move is part of Novo's strategy to maintain market share amid increasing competition, as several Indian firms have launched their own versions of semaglutide at significantly lower prices. The changes reflect the growing demand for metabolic treatments in India, which has a large population of type 2 diabetes patients and rising obesity rates.

Read full article: https://www.tradingview.com/news/invezz:ff0d92d91094b:0-novo-cuts-ozempic-wegovy-prices-up-to-48-as-generics-surge/

Subscribe to our real-time email alerts: https://www.stellarint.ai/Services/

Novo Nordisk has launched a multi-month subscription program for its FDA-approved weight loss medication, Wegovy (semaglutide), aimed at helping eligible self-pay patients manage costs. Starting March 31, 2026, the program will be available through select telehealth providers, offering predictable monthly pricing and potential savings of up to $1,200 per year. The subscription options include 3-, 6-, or 12-month plans, with lower monthly rates for longer commitments. Wegovy is designed to assist adults with obesity in achieving significant weight loss and reducing the risk of major cardiovascular events. The program is part of Novo Nordisk's broader strategy to enhance access to obesity treatment and support long-term weight management. Wegovy is also available through over 70,000 pharmacies and NovoCare Pharmacy, with additional savings for those with commercial insurance.

Read full article: https://www.prnewswire.com/news-releases/novo-nordisk-launches-first-and-only-multi-month-subscription-program-for-fda-approved-wegovy-offering-savings-of-up-to-1-200year-302729943.html

Subscribe to our real-time email alerts: https://www.stellarint.ai/Services/

Aardvark Therapeutics, Inc. has paused its Phase 3 HERO and open-label extension trials of ARD-101 for Prader-Willi syndrome, as well as the ARD-201 obesity program, due to cardiac findings from a healthy volunteer study. The company reported that two participants in a cohort dosed at 1,600 mg twice daily experienced significant QRS increases, while another cohort dosed at 800 mg twice daily had similar observations. These findings were reversible and not classified as serious adverse events. Aardvark is collaborating with the FDA to determine next steps and expects to provide updates in the second quarter of 2026. The company ended 2025 with $110 million in cash, which is projected to fund operations into the second quarter of 2027.

Read full article: https://finance.yahoo.com/sectors/healthcare/articles/why-aardvark-therapeutics-aard-paused-204232901.html

Subscribe to our real-time email alerts: https://www.stellarint.ai/Services/

💊 kardigan 🫀 hypertension
Kardigan, a hypertension drug, faced challenges in its Phase 2 trial, missing its primary endpoint related to blood pressure reduction. Despite achieving a biomarker win, the overall results did not meet expectations, raising concerns about the drug's efficacy in treating hypertension.

Read full article: https://www.fiercebiotech.com/biotech/kardigan-hypertension-drug-tangles-biomarker-win-blood-pressure-miss-phase-2-trial

Subscribe to our real-time email alerts: https://www.stellarint.ai/Services/

Seismic Pharma, a newly established biopharmaceutical company, has been formed to advance a portfolio of clinical-stage therapies for heart failure, with initial financing led by Panacea Capital. The company aims to develop Phase 3-ready drug candidates, including istaroxime, which is designed for treating cardiogenic shock and has shown promise in improving cardiac function without the safety issues of traditional therapies. Seismic Pharma's portfolio also includes next-generation treatments targeting acute and advanced heart failure, addressing significant unmet needs in cardiovascular medicine. The company plans to complete its first Phase 3 study for istaroxime by 2027 and is focused on advancing its oral heart failure program towards first-in-human studies by the same year. Seismic Pharma's founding portfolio was acquired from Windtree Therapeutics, and the company is headquartered in Durham, North Carolina.

Read full article: https://www.biospace.com/press-releases/panacea-capital-leads-formation-of-seismic-pharma-to-advance-novel-clinical-stage-heart-failure-portfolio

Subscribe to our real-time email alerts: https://www.stellarint.ai/Services/

Merck & Co., Inc. announced positive Phase 2 CADENCE trial results for WINREVAIR (sotatercept-csrk), which demonstrated a significant reduction in pulmonary vascular resistance in adults with combined post- and precapillary pulmonary hypertension and heart failure with preserved ejection fraction. The drug also showed promising trends in various clinical measures, suggesting it could provide a new treatment option in a challenging cardiovascular area. Despite these encouraging results, Merck's future revenue and earnings projections remain heavily influenced by the impending patent expiration of its key product, KEYTRUDA. The company is also pursuing acquisitions, such as Terns Pharmaceuticals, to diversify its portfolio. Analysts have mixed views on Merck's financial outlook, with some projecting lower revenue and earnings growth than the company aims for by 2028. The article emphasizes the importance of evaluating Merck's pipeline and acquisitions in light of its current valuation and market pressures.

Read full article: https://finance.yahoo.com/sectors/healthcare/articles/investors-may-respond-merck-mrk-130849197.html

Subscribe to our real-time email alerts: https://www.stellarint.ai/Services/

Revelation Biosciences Inc. presented additional positive data from its PRIME clinical study at the International Conference on Advances in Critical Care Nephrology. The study demonstrated that Gemini, a proprietary formulation of phosphorylated hexaacyl disaccharide, effectively normalized cellular inflammation and restored immunocompetence in patients with stage 3 and 4 chronic kidney disease (CKD) after a single dose. Over 85% of patients had elevated cytokines before treatment, and Gemini significantly reduced these levels at various time points post-dose. The company plans to initiate a pivotal Phase 2/3 clinical study for acute kidney injury (AKI) later this year, as Gemini is also being developed for CKD. Revelation aims to address the urgent need for new therapies in inflammation-driven diseases, particularly AKI, which affects a significant portion of hospitalized patients.

Read full article: https://www.biospace.com/press-releases/revelation-biosciences-inc-presents-additional-positive-data-from-prime-clinical-study

Subscribe to our real-time email alerts: https://www.stellarint.ai/Services/

Lexeo Therapeutics, Inc. has made significant progress in its clinical pipeline, particularly with LX2006 for Friedreich Ataxia and LX2020 for PKP2 Arrhythmogenic Cardiomyopathy. The company submitted the protocol for the SUNRISE-FA 2 pivotal trial to the FDA and is on track to initiate the study in the first half of 2026. Positive interim clinical data for both LX2006 and LX2020 were presented at the American College of Cardiology Annual Meeting, showing improvements in cardiac and functional outcomes. Lexeo has also strengthened its leadership team and established a collaboration with Johnson & Johnson for targeted cardiac gene therapy delivery. The company reported a cash position of $246.6 million, expected to fund operations into 2028, and detailed its financial results for 2025, including a net loss of $100 million for the year.

Read full article: https://www.globenewswire.com/news-release/2026/03/30/3265004/0/en/Lexeo-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Operational-Highlights.html

Subscribe to our real-time email alerts: https://www.stellarint.ai/Services/

Biomea Fusion is advancing its lead menin inhibitor, icovamenib, for diabetes, with clinical milestones including imminent enrollment in two trials (COVALENT-211 and COVALENT-212) targeting approximately 60 patients each, aiming for 26-week readouts by year-end. The company also plans to report 52-week data from a type 1 diabetes proof-of-concept trial in Q2. Biomea's obesity program, BMF-650, is in Phase 1, with multiple-ascending-dose data expected by the end of Q2 and an initial readout anticipated in Q2 2026. The company emphasizes the role of menin inhibition in pancreatic beta-cell biology and its potential benefits in diabetes management, while also discussing patient selection and dosing strategies based on previous trial learnings. Biomea believes it has a strong intellectual property position for its therapies and aims to validate early clinical signals in upcoming Phase 2 studies.

Read full article: https://finance.yahoo.com/sectors/healthcare/articles/biomea-fusion-details-icovamenib-diabetes-210324448.html

Subscribe to our real-time email alerts: https://www.stellarint.ai/Services/

Unicycive Therapeutics, Inc. announced that its New Drug Application (NDA) resubmission for oxylanthanum carbonate (OLC) is under review by the U.S. FDA, with a target action date of June 29, 2026. The company is preparing for a potential commercial launch in the third quarter of 2026. As of March 30, 2026, Unicycive reported unaudited cash and marketable securities totaling $54.9 million, expected to fund operations into 2027. The NDA for OLC, an investigational oral phosphate binder for treating hyperphosphatemia in chronic kidney disease patients on dialysis, is supported by data from multiple clinical studies. The company reported a net loss of $26.6 million for the year ended December 31, 2025, a decrease from the previous year's loss, attributed to reduced drug development and clinical trial costs. Unicycive is also developing UNI-494 for acute kidney injury, which has received orphan drug designation from the FDA.

Read full article: https://www.globenewswire.com/news-release/2026/03/30/3264502/0/en/Unicycive-Therapeutics-Announces-Full-Year-2025-Financial-Results-and-Provides-Business-Update.html

Subscribe to our real-time email alerts: https://www.stellarint.ai/Services/

Wave Life Sciences Ltd. (WVE) has had its price target increased to $52 from $43 by Canaccord Genuity, maintaining a Buy rating following a review of its pipeline, which includes WVE-007 for obesity and WVE-006 for alpha-1 antitrypsin deficiency (AATD). This update comes after the company confirmed that data from its RestorAATion-2 clinical trial of WVE-006 will be presented at the American Thoracic Society International Conference in May 2026. The trial results will include data from both the 400 mg multidose and 600 mg single-dose cohorts. Wave Life Sciences is also on track to release data from the INLIGHT trial for WVE-007 targeting obesity later this month. The company is focused on developing RNA editing therapies to address genetic diseases and is in discussions for potential accelerated approval for WVE-006, with feedback expected in mid-2026.

Read full article: https://finance.yahoo.com/markets/stocks/articles/wave-life-sciences-ltd-wve-114002630.html

Subscribe to our real-time email alerts: https://www.stellarint.ai/Services/

Kailera Therapeutics, a biotech company focused on obesity treatments, has filed for an initial public offering (IPO) in the US, aiming to attract investors with its weight loss drug pipeline. The company, based in Waltham, Massachusetts, recently reported positive phase 2 results for its oral dual GIP and GLP-1 agonist ribupatide (KAI9531), which showed a 12% weight reduction over 26 weeks. An injectable version of the drug is in phase 3 trials, having achieved a 23.6% weight loss in phase 2. Kailera's IPO follows a successful $600 million Series B financing and a $400 million Series A. The proposed IPO amount is $100 million, though it may increase due to gh demand for obesity-related investments. Kailera plans to list on Nasdaq under the symbol KLRA and has initiated phase 3 trials for ribupatide, with results expected in 2028. The company is also advancing other candidates in its pipeline, including KAI-7535 and KAI-4729, with various trials planned for this year and beyond.

Read full article: https://pharmaphorum.com/news/obesity-focused-biotech-kailera-joins-ipo-queue-us

Subscribe to our real-time email alerts: https://www.stellarint.ai/Services/

Evolocumab, a PCSK9 inhibitor, has been shown to reduce the risk of major cardiovascular (CV) events in patients with diabetes but without known atherosclerosis, according to a subgroup analysis of the VESALIUS-CV trial. The study involved 3,655 gh-risk patients who had gh LDL levels and were on stable statin therapy. Results indicated that at 48 weeks, the median LDL was significantly lower in the evolocumab group compared to placebo, and at a median follow-up of 4.8 years, the first primary endpoint of CV death, myocardial infarction (MI), or ischemic stroke occurred in 5% of the evolocumab group versus 7.1% in the placebo group. The findings suggest that aggressive LDL lowering may benefit a broader population of patients with diabetes, potentially changing clinical practice regarding lipid management in this group. The study was presented at the American College of Cardiology Scientific Session and published in JAMA.

Read full article: https://www.healio.com/news/cardiology/20260329/evolocumab-lowers-cv-event-risk-in-diabetes-without-known-atherosclerosis

Subscribe to our real-time email alerts: https://www.stellarint.ai/Services/

BioNxt Solutions Inc. has announced the advancement of its semaglutide oral thin-film (ODF) program, marking the first application of its broader GLP-1 receptor agonist platform strategy. The company is in the early stages of developing this program, focusing on formulation work and proof-of-concept evaluations for semaglutide, a widely used treatment for type 2 diabetes and obesity. BioNxt aims to establish a scalable platform for the sublingual delivery of peptide therapeutics, with plans to expand to other GLP-1 compounds. The global market for GLP-1 receptor agonists is rapidly growing, projected to reach USD 254.19 billion by 2034. BioNxt's strategy emphasizes drug delivery innovation and lifecycle management opportunities for established drugs, with an initial focus on metabolic and peptide-based indications. The company is also working on developing intellectual property related to its formulation and delivery technologies.

Read full article: https://www.morningstar.com/news/accesswire/1152951msn/bionxt-advances-semaglutide-as-first-application-of-broad-glp-1-odf-platform-strategy

Subscribe to our real-time email alerts: https://www.stellarint.ai/Services/